Federated Causal Inference: Multi-Source ATE Estimation beyond Meta-Analysis

Rémi Khellaf

Supervised by Aurélien Bellet & Julie Josse November 27, 2024

PreMeDICal team, INRIA, INSERM, Université de Montpellier

Motivation

• Goal of causal inference: measure the (average) impact of a treatment on an outcome

- Goal of causal inference: measure the (average) impact of a treatment on an outcome
 - Medical studies: impact of vaccination on Covid-19 outbreaks? (Moghadas et al., 2021)

- Goal of causal inference: measure the (average) impact of a treatment on an outcome
 - Medical studies: impact of vaccination on Covid-19 outbreaks? (Moghadas et al., 2021)
 - Economics and social sciences: impact of studies on future earnings in developing countries? (Duflo, Glennerster, and Kremer, 2007)

- Goal of causal inference: measure the (average) impact of a treatment on an outcome
 - Medical studies: impact of vaccination on Covid-19 outbreaks? (Moghadas et al., 2021)
 - Economics and social sciences: impact of studies on future earnings in developing countries? (Duflo, Glennerster, and Kremer, 2007)
 - Public Health & Economy: evaluating drugs efficacy. French social security reimburses drugs based on their proven efficacy. (French Health Authority, 2024)

- Goal of causal inference: measure the (average) impact of a treatment on an outcome
- Experimental method: randomized clinical trials (RCTs) are the gold standard

- Goal of causal inference: measure the (average) impact of a treatment on an outcome
- Experimental method: randomized clinical trials (RCTs) are the gold standard
 - Randomization of treatment assignment disentangles correlation from causation: differences in outcomes are attributable to the treatment only rather than confounding factors



- Goal of causal inference: measure the (average) impact of a treatment on an outcome
- Experimental method: randomized clinical trials (RCTs) are the gold standard
 - Randomization of treatment assignment disentangles correlation from causation: differences in outcomes are attributable to the treatment only rather than confounding factors
 - Limits: expensive, not always feasible, stringent eligibility criteria, short timeframes, small sample sizes

- Goal of causal inference: measure the (average) impact of a treatment on an outcome
- Experimental method: randomized clinical trials (RCTs) are the gold standard
 - Randomization of treatment assignment disentangles correlation from causation: differences in outcomes are attributable to the treatment only rather than confounding factors
 - Limits: expensive, not always feasible, stringent eligibility criteria, short timeframes, small sample sizes
 - $\rightarrow\,$ Multisource approach: several RCTs are better than 1!







- Goal of causal inference: measure the (average) impact of a treatment on an outcome
- Experimental method: randomized clinical trials (RCTs) are the gold standard
- Multisource framework: meta-analysis on summary statistics as the top of the pyramid of evidence



- Goal of causal inference: measure the (average) impact of a treatment on an outcome
- Experimental method: randomized clinical trials (RCTs) are the gold standard
- Multisource framework: meta-analysis on summary statistics as the top of the pyramid of evidence
 - Aggregates estimated causal effects from published summary statistics of multiple studies



- Goal of causal inference: measure the (average) impact of a treatment on an outcome
- Experimental method: randomized clinical trials (RCTs) are the gold standard
- Multisource framework: meta-analysis on summary statistics as the top of the pyramid of evidence
 - Aggregates estimated causal effects from published summary statistics of multiple studies



- Goal of causal inference: measure the (average) impact of a treatment on an outcome
- Experimental method: randomized clinical trials (RCTs) are the gold standard
- Multisource framework: meta-analysis on summary statistics as the top of the pyramid of evidence
 - Aggregates estimated causal effects from published summary statistics of multiple studies
 - Increased statistical power and more precise estir
 - Keeps the data decentralized





- Goal of causal inference: measure the (average) impact of a treatment on an outcome
- Experimental method: randomized clinical trials (RCTs) are the gold standard
- Multisource framework: meta-analysis on summary statistics as the top of the pyramid of evidence
 - Aggregates estimated causal effects from published summary statistics of multiple studies
 - Increased statistical power and more precise estimates
 - Keeps the data decentralized
 - Limits: no direct access of individual observations \implies face important challenges in presence of heterogeneity between the studies



- Goal of causal inference: measure the (average) impact of a treatment on an outcome
- Experimental method: randomized clinical trials (RCTs) are the gold standard
- Multisource framework: meta-analysis on summary statistics as the top of the pyramid of evidence
- Our contribution: leverage federated learning (FL) to perform causal inference on decentralized invidividual data



- Goal of causal inference: measure the (average) impact of a treatment on an outcome
- Experimental method: randomized clinical trials (RCTs) are the gold standard
- Multisource framework: meta-analysis on summary statistics as the top of the pyramid of evidence
- Our contribution: leverage federated learning (FL) to perform causal inference on decentralized invidividual data
 - Propose the Gradient Descent Federated estimator of the Average Treatment Effect (ATE)

- Goal of causal inference: measure the (average) impact of a treatment on an outcome
- Experimental method: randomized clinical trials (RCTs) are the gold standard
- Multisource framework: meta-analysis on summary statistics as the top of the pyramid of evidence
- Our contribution: leverage federated learning (FL) to perform causal inference on decentralized invidividual data
 - Propose the Gradient Descent Federated estimator of the Average Treatment Effect (ATE)
 - Study and compare (bias and asymptotic variances) Meta-Analysis, One-Shot federated and Gradient Descent federated estimators of ATE

- Goal of causal inference: measure the (average) impact of a treatment on an outcome
- Experimental method: randomized clinical trials (RCTs) are the gold standard
- Multisource framework: meta-analysis on summary statistics as the top of the pyramid of evidence
- Our contribution: leverage federated learning (FL) to perform causal inference on decentralized invidividual data
 - Propose the Gradient Descent Federated estimator of the Average Treatment Effect (ATE)
 - Study and compare (bias and asymptotic variances) Meta-Analysis, One-Shot federated and Gradient Descent federated estimators of ATE
 - Compare their robustness to several heterogeneity scenarios

Introduction to Causal Inference

• Causal inference goal: estimate the (average) impact of **treatment** *W* on *Y*, given *X* describing a population.

- Causal inference goal: estimate the (average) impact of **treatment** *W* on *Y*, given *X* describing a population.
- Data is centralized:

Obs.	C	ovariat	es	Treatment	Outcome	Potentia	al Outcomes
i	X_1	X_2	X_3	W	Y	$Y^{(1)}$	$Y^{(0)}$
1	2.3	1.5	М	1	3.2	3.2	??
2	2.2	3.1	F	0	2.8	??	2.8
3	3.5	2.0	F	1	2.1	2.1	??
÷	÷	÷	÷	÷	:	:	:
n-1	3.7	2.0	F	0	2.8	??	2.8
п	2.5	1.7	М	1	3.2	3.2	??

- Causal inference goal: estimate the (average) impact of **treatment** *W* on *Y*, given *X* describing a population.
- Data is centralized:

Obs.	Covariates		Treatment	Outcome	Potentia	al Outcomes	
i	X_1	X_2	X_3	W	Y	$Y^{(1)}$	Y ⁽⁰⁾
1	2.3	1.5	М	1	3.2	3.2	??
2	2.2	3.1	F	0	2.8	??	2.8
3	3.5	2.0	F	1	2.1	2.1	??
:	÷	÷	÷	:	:		:
n-1	3.7	2.0	F	0	2.8	??	2.8
n	2.5	1.7	М	1	3.2	3.2	??

Average Treatment Effect (ATE)

measured as a risk difference:

 $\tau = \mathbb{E}\left(Y_i(1) - Y_i(0)\right)$

- Causal inference goal: estimate the (average) impact of **treatment** *W* on *Y*, given *X* describing a population.
- Data is centralized:

Obs.	Covariates		Treatment	Outcome	Potentia	al Outcomes	
i	<i>X</i> ₁	<i>X</i> ₂	<i>X</i> ₃	W	Y	$Y^{(1)}$	$Y^{(0)}$
1	2.3	1.5	М	1	3.2	3.2	??
2	2.2	3.1	F	0	2.8	??	2.8
3	3.5	2.0	F	1	2.1	2.1	??
:	÷	÷	÷	:	÷		÷
n-1	3.7	2.0	F	0	2.8	??	2.8
n	2.5	1.7	М	1	3.2	3.2	??

Average Treatment Effect (ATE)

measured as a risk difference:

$$egin{aligned} & au = \mathbb{E}\left(Y_i(1) - Y_i(0)
ight) \ & = \mathbb{E}\left(\mathbb{E}\left(Y_i(1) \mid oldsymbol{X}_i
ight) - \mathbb{E}\left(Y_i(0) \mid oldsymbol{X}_i
ight)
ight) \end{aligned}$$

- Causal inference goal: estimate the (average) impact of **treatment** *W* on *Y*, given *X* describing a population.
- Data is centralized:

Obs.	Covariates		Treatment	Outcome	Potential Outcomes		
i	X_1	X_2	X_3	W	Y	$Y^{(1)}$	$Y^{(0)}$
1	2.3	1.5	М	1	3.2	3.2	??
2	2.2	3.1	F	0	2.8	??	2.8
3	3.5	2.0	F	1	2.1	2.1	??
•	:	:	÷	:	÷	:	:
n-1	3.7	2.0	F	0	2.8	??	2.8
п	2.5	1.7	М	1	3.2	3.2	??

Average Treatment Effect (ATE)

measured as a risk difference:

$$\begin{aligned} r &= \mathbb{E}\left(Y_i(1) - Y_i(0)\right) \\ &= \mathbb{E}\left(\mathbb{E}\left(Y_i(1) \mid X_i\right) - \mathbb{E}\left(Y_i(0) \mid X_i\right)\right) \\ &= \mathbb{E}\left(\mathbb{E}\left(Y_i(1) \mid W_i = 1, X_i\right) \\ &- \mathbb{E}\left(Y_i(0) \mid W_i = 0, X_i\right)\right) \quad (a) \end{aligned}$$

(a) Unconfoundedness: $W_i \perp \{Y_i(1), Y_i(0)\}$ RCTs: $W_i \sim \mathcal{B}(p_i)$, $\implies W_i \perp X_i$

- Causal inference goal: estimate the (average) impact of **treatment** *W* on *Y*, given *X* describing a population.
- Data is centralized:

Obs.	Covariates		Treatment	Outcome	Potentia	al Outcomes	
i	X_1	X_2	X_3	W	Y	$Y^{(1)}$ $Y^{(0)}$	
1	2.3	1.5	М	1	3.2	3.2	??
2	2.2	3.1	F	0	2.8	??	2.8
3	3.5	2.0	F	1	2.1	2.1	??
	:	:	÷	:	:	:	÷
n-1	3.7	2.0	F	0	2.8	??	2.8
п	2.5	1.7	М	1	3.2	3.2	??

Average Treatment Effect (ATE)

measured as a risk difference:

$$\begin{aligned} \tau &= \mathbb{E}\left(Y_{i}(1) - Y_{i}(0)\right) \\ &= \mathbb{E}\left(\mathbb{E}\left(Y_{i}(1) \mid X_{i}\right) - \mathbb{E}\left(Y_{i}(0) \mid X_{i}\right)\right) \\ &= \mathbb{E}\left(\mathbb{E}\left(Y_{i}(1) \mid W_{i} = 1, X_{i}\right) \\ &- \mathbb{E}\left(Y_{i}(0) \mid W_{i} = 0, X_{i}\right)\right) \quad \text{(a)} \\ &= \mathbb{E}\left(\mathbb{E}\left(Y_{i} \mid W_{i} = 1, X_{i}\right) \\ &- \mathbb{E}\left(Y_{i} \mid W_{i} = 0, X_{i}\right)\right) \quad \text{(b)} \end{aligned}$$

(b) Consistency: $Y_i = W_i Y_i(1) + (1 - W_i) Y_i(0)$

- Causal inference goal: estimate the (average) impact of **treatment** *W* on *Y*, given *X* describing a population.
- Data is centralized:

Obs.	Covariates		Treatment	Outcome	Potentia	al Outcomes	
i	X_1	X_2	X_3	W	Y	$Y^{(1)}$ $Y^{(0)}$	
1	2.3	1.5	М	1	3.2	3.2	??
2	2.2	3.1	F	0	2.8	??	2.8
3	3.5	2.0	F	1	2.1	2.1	??
÷	÷	÷	÷	:	÷	:	:
n-1	3.7	2.0	F	0	2.8	??	2.8
п	2.5	1.7	М	1	3.2	3.2	??

Unbiased ATE estimation:

$$\hat{\tau}_{\rm DM} = \overline{Y_{|W=1}} - \overline{Y_{|W=0}}$$

- Causal inference goal: estimate the (average) impact of **treatment** *W* on *Y*, given *X* describing a population.
- Data is centralized:

Obs.	C	Covariates		Treatment	Outcome	Potentia	al Outcomes
i	X_1	X_2	X_3	W	Y	$Y^{(1)}$	$Y^{(0)}$
1	2.3	1.5	М	1	3.2	3.2	2.4
2	2.2	3.1	F	0	2.8	3.5	2.8
3	3.5	2.0	F	1	2.1	2.1	2.1
÷	÷	÷	÷	:	÷	:	:
n-1	3.7	2.0	F	0	2.8	3.7	2.8
п	2.5	1.7	М	1	3.2	3.2	2.9

Unbiased ATE estimation:

• Difference-in-Means:

$$\hat{\tau}_{\rm DM} = \overline{Y_{|W=1}} - \overline{Y_{|W=0}}$$

• Covariate-adjusted G-Formula: $\hat{\tau}_{\rm G} = \frac{1}{n} \sum_{i=1}^{n} \left(\hat{\mu}_1(X_i) - \hat{\mu}_0(X_i) \right)$

- Causal inference goal: estimate the (average) impact of **treatment** *W* on *Y*, given *X* describing a population.
- Data is centralized:

Obs.	C	Covariates		Treatment	Outcome	Potentia	ntial Outcomes	
i	X_1	X_2	X_3	W	Y	$Y^{(1)}$	$Y^{(0)}$	
1	2.3	1.5	М	1	3.2	3.2	2.4	
2	2.2	3.1	F	0	2.8	3.5	2.8	
3	3.5	2.0	F	1	2.1	2.1	2.1	
:	÷	÷	÷	:	÷		÷	
n-1	3.7	2.0	F	0	2.8	3.7	2.8	
п	2.5	1.7	М	1	3.2	3.2	2.9	

Unbiased ATE estimation:

• Difference-in-Means:

$$\hat{\tau}_{\rm DM} = \overline{Y_{|W=1}} - \overline{Y_{|W=0}}$$

• Linearly-adjusted G-Formula: $\hat{\tau}_{\text{OLS}} = \frac{1}{n} \sum_{i=1}^{n} \left(X_i \hat{\beta}^{(1)} - \frac{X_i \hat{\beta}^{(0)}}{X_i \hat{\beta}^{(0)}} \right)$

- Causal inference goal: estimate the (average) impact of **treatment** *W* on *Y*, given *X* describing a population.
- Data is centralized:

Obs.	C	Covariates		Treatment	Outcome	Potentia	al Outcomes
i	X_1	X_2	X_3	W	Y	$Y^{(1)}$ $Y^{(0)}$	
1	2.3	1.5	М	1	3.2	3.2	??
2	2.2	3.1	F	0	2.8	??	2.8
3	3.5	2.0	F	1	2.1	2.1	??
:	÷	÷	÷	:	÷	:	÷
n-1	3.7	2.0	F	0	2.8	??	2.8
п	2.5	1.7	М	1	3.2	3.2	??

Unbiased ATE estimation:

• Difference-in-Means:

$$\hat{\tau}_{\rm DM} = \overline{Y_{|W=1}} - \overline{Y_{|W=0}}$$

• Linearly-adjusted G-Formula: $\hat{\tau}_{OLS} = \frac{1}{n} \sum_{i=1}^{n} (X_i \hat{\beta}^{(1)} - X_i \hat{\beta}^{(0)})$ with $\hat{\beta}^{(w)}$ the OLS regressor learned on individuals with W = w.

Refs.: U.S. Food and Drug Administration, 2023, European

Medicines Agency, 2024, Tsiatis et al., 2008, Benkeser et al.,

2021, Lin, 2013, Wager, 2020, Lei and Ding, 2021,

Van Lancker, Bretz, and Dukes, 2024

Main Motivation: $|\mathbb{V}(\hat{\tau}_{\text{OLS}}) \leq \mathbb{V}(\hat{\tau}_{\text{DM}})$ even when μ_1 and μ_0 are not linear functions!

- **Multisource** inference goal: estimate the impact of *W* on *Y* given *X* describing a population, split across *K* studies.
- Data is decentralized:

Source	Obs.	C	ovariate	es	Treatment	Outcomes
Н	i	X_1	X_2	X_3	W	Y
1	1	2.3	1.5	М	1	3.2
1	2	2.2	3.1	F	0	2.8
÷	:	÷	:	÷	:	÷
2	1	4.5	5.0	F	1	4.1
:	:	÷	:	÷	:	:
К	1	3.7	2.0	F	0	2.8
:	:	÷	:	÷	:	÷
К	n _K	2.5	1.7	М	0	3.2



- **Multisource** inference goal: estimate the impact of *W* on *Y* given *X* describing a population, split across *K* studies.
- Data is decentralized:

Source	Obs.	Covariates		es	Treatment	Outcomes	
Н	i	X_1	X_2	X_3	W	Y	$\mathbb{P}(W_i)$
1	1	2.3	1.5	М	1	3.2	p_1
1	2	2.2	3.1	F	0	2.8	ρ_1
÷	÷	÷	÷	÷	:	÷	÷
2	1	4.5	5.0	F	1	4.1	<i>p</i> ₂
:	:	:	÷	÷		÷	÷
К	1	3.7	2.0	F	0	2.8	<i>p</i> ₃
:	÷	÷	÷	÷	:	÷	÷
К	n _K	2.5	1.7	М	0	3.2	<i>p</i> ₃

Heterogeneity in treatment allocation



$$au = \mathbb{E}\left(\mathbb{E}\left(Y^{(1)} - Y^{(0)} \mid H
ight)
ight)$$

- **Multisource** inference goal: estimate the impact of *W* on *Y* given *X* describing a population, split across *K* studies.
- Data is decentralized:

Source	Obs.	Covariates		Treatment	Outcomes		
Н	i	X_1	X_2	X_3	W	Y	\mathcal{D}
1	1	2.3	1.5	М	1	3.2	\mathcal{D}_1
1	2	2.2	3.1	F	0	2.8	\mathcal{D}_1
÷	÷	÷	÷	÷	•	÷	÷
2	1	4.5	5.0	F	1	4.1	\mathcal{D}_2
:	:	÷	÷	÷	•	÷	:
K	1	3.7	2.0	F	0	2.8	\mathcal{D}_3
:	÷	÷	÷	÷	:	:	÷
K	n _K	2.5	1.7	М	0	3.2	\mathcal{D}_3

Heterogeneity in covariates distribution



$$au = \mathbb{E}\left(\mathbb{E}\left(Y^{(1)} - Y^{(0)} \mid H
ight)
ight)$$

• **Multisource** inference goal: estimate the impact of *W* on *Y* given *X* describing a population, split across *K* studies.

• Data is decentralized:

Source	Obs.	Covariates			Treatment	Outcomes	
Н	i	X_1	X_2	X_3	W	Y	+ cste
1	1	2.3	1.5	Μ	1	3.2	h_1
1	2	2.2	3.1	F	0	2.8	h_1
:	÷	÷	÷	÷	:	÷	:
2	1	4.5	5.0	F	1	4.1	h ₂
÷	÷	÷	÷	÷	:	÷	÷
К	1	3.7	2.0	F	0	2.8	h ₃
:	÷	÷	÷	÷	:	÷	:
К	n _K	2.5	1.7	Μ	0	3.2	h ₃

Heterogeneity in center effects



Federated Causal Inferences: estimation strategies






 Meta-analysis: average-weighted aggregation of local estimates
 →
 ^ˆ = ∑^K_{k=1} w_k
 ^ˆ_k



- Meta-analysis: average-weighted aggregation of local estimates $\rightarrow \hat{\tau} = \sum_{k=1}^{K} w_k \hat{\tau}_k$
- Federated estimation:



• Meta-analysis: average-weighted aggregation of local estimates

$$o \hat{ au} = \sum_{k=1}^{K} w_k \hat{ au}_k$$

- Federated estimation:
 - a. Learn the parameters for the outcome and/or propensity score models



 Meta-analysis: average-weighted aggregation of local estimates

$$ightarrow \hat{ au} = \sum_{k=1}^{K} w_k \hat{ au}_k$$

- Federated estimation:
 - a. Learn the parameters for the outcome and/or propensity score models
 - b. Build a global estimate $\hat{\tau}$ from these models (e.g., G-Formula, IPW, AIPW).

Multi-sources ATE Estimation

• Denote $X_k^{(w)}$ (resp. $Y_k^{(w)}$) the covariates matrix (resp. outcome vector) of study k under treatment arm w

- Denote X^(w)_k (resp. Y^(w)_k) the covariates matrix (resp. outcome vector) of study k under treatment arm w
- Linear outcome model: $\forall k, Y_{k,i}^{(w)} = c^{(w)} + X_{k,i}\beta^{(w)} + \varepsilon_{k,i}^{(w)}$ with $w \in \{0, 1\}$.

- Denote X^(w)_k (resp. Y^(w)_k) the covariates matrix (resp. outcome vector) of study k under treatment arm w
- Linear outcome model: $\forall k, Y_{k,i}^{(w)} = c^{(w)} + X_{k,i}\beta^{(w)} + \varepsilon_{k,i}^{(w)}$ with $w \in \{0, 1\}$.
- $\rightarrow \text{ Goal: estimate } \tau := \mathbb{E}\left(\mathbb{E}(Y_i^{(1)} Y_i^{(0)} \mid H_i)\right) = c^{(1)} c^{(0)} + \mathbb{E}(\mathbb{E}(X_i \mid H_i))(\beta^{(1)} \beta^{(0)}).$

- Denote X^(w)_k (resp. Y^(w)_k) the covariates matrix (resp. outcome vector) of study k under treatment arm w
- Linear outcome model: $\forall k, Y_{k,i}^{(w)} = c^{(w)} + X_{k,i}\beta^{(w)} + \varepsilon_{k,i}^{(w)}$ with $w \in \{0, 1\}$.

Local causality assumptions:

- Consistency: $\forall i, Y_i = W_i Y_i^{(1)} + (1 W_i) Y_i^{(0)}$
- Positivity: $\forall x \in \mathcal{X}, \exists \eta > 0 \text{ s.t. } \eta \leq \mathbb{P}(W_i = 1 \mid X_i = x) \leq 1 \eta$
- Unconfoundedness: $W_i \perp \{Y_i^{(1)}, Y_i^{(0)}\} | X_i, H_i$

- Denote X^(w)_k (resp. Y^(w)_k) the covariates matrix (resp. outcome vector) of study k under treatment arm w
- Linear outcome model: $\forall k, Y_{k,i}^{(w)} = c^{(w)} + X_{k,i}\beta^{(w)} + \varepsilon_{k,i}^{(w)}$ with $w \in \{0, 1\}$.

Regression assumptions:

•
$$\forall (k, w), \mathbb{E}(X_k^{\top} \varepsilon(w)) = 0, \mathbb{V}(\varepsilon(w) \mid X_k) = \sigma^2$$
,

• Local Full Rank: rank $(X_k^{\top}X_k) = d$

- Denote X^(w)_k (resp. Y^(w)_k) the covariates matrix (resp. outcome vector) of study k under treatment arm w
- Linear outcome model: $\forall k, Y_{k,i}^{(w)} = c^{(w)} + X_{k,i}\beta^{(w)} + \varepsilon_{k,i}^{(w)}$ with $w \in \{0, 1\}$.

Pool G-Formula estimator:

$$\hat{\tau} = rac{1}{n}\sum_{i=1}^{n}\left(\hat{\mu}_{1}(X) - \hat{\mu}_{0}(X)\right) = rac{1}{n}\sum_{i=1}^{n}X_{i}(\hat{\theta}_{\mathrm{pool}}^{(1)} - \hat{\theta}_{\mathrm{pool}}^{(0)})$$

with $\hat{\theta}_{\text{pool}}^{(w)} = \{\hat{c}_{\text{pool}}^{(w)}, \hat{\beta}_{\text{pool}}^{(w)}\}$ the OLS regressor over the pooled dataset.

- Denote X^(w)_k (resp. Y^(w)_k) the covariates matrix (resp. outcome vector) of study k under treatment arm w
- Linear outcome model: $\forall k, Y_{k,i}^{(w)} = c^{(w)} + X_{k,i}\beta^{(w)} + \varepsilon_{k,i}^{(w)}$ with $w \in \{0, 1\}$.

Pool G-Formula estimator:

$$\hat{\tau} = \frac{1}{n} \sum_{i=1}^{n} \left(\hat{\mu}_1(X) - \hat{\mu}_0(X) \right) = \frac{1}{n} \sum_{i=1}^{n} X_i \left(\hat{\theta}_{\text{pool}}^{(1)} - \hat{\theta}_{\text{pool}}^{(0)} \right)$$

with $\hat{\theta}_{\text{pool}}^{(w)} = \{\hat{c}_{\text{pool}}^{(w)}, \hat{\beta}_{\text{pool}}^{(w)}\}$ the OLS regressor over the pooled dataset. \rightarrow Problem: we do not have access to the pooled dataset !

- Denote X^(w)_k (resp. Y^(w)_k) the covariates matrix (resp. outcome vector) of study k under treatment arm w
- Linear outcome model: $\forall k, Y_{k,i}^{(w)} = c^{(w)} + X_{k,i}\beta^{(w)} + \varepsilon_{k,i}^{(w)}$ with $w \in \{0, 1\}$.

Pool G-Formula estimator:

$$\hat{\tau} = \frac{1}{n} \sum_{i=1}^{n} \left(\hat{\mu}_1(X) - \hat{\mu}_0(X) \right) = \frac{1}{n} \sum_{i=1}^{n} X_i (\hat{\theta}_{\text{pool}}^{(1)} - \hat{\theta}_{\text{pool}}^{(0)})$$

with $\hat{\theta}_{\text{pool}}^{(w)} = \{\hat{c}_{\text{pool}}^{(w)}, \hat{\beta}_{\text{pool}}^{(w)}\}$ the OLS regressor over the pooled dataset.

- \rightarrow Problem: we do not have access to the pooled dataset !
- \rightarrow Need to consider other estimation strategies for $\hat{\tau}.$

Meta vs. (One Shot) Federated G-Formula



Meta vs. (One Shot) Federated G-Formula



Meta vs. (One Shot) Federated G-Formula



Comparison of the Estimators

Homogeneous setting

Homogeneous population setting:



Figure 1: Graphical model: K RCTs

 $\implies \forall \{k, i\}, W_{k,i} \sim \mathcal{B}(p_k), \text{ different}$ treatment allocation schemes.

Under an Homogeneous setting, all estimators are unbiased and:

Estimator	Notation	\mathbb{V}^{∞}	Com. rounds	Com. cost
Meta-SW	$\hat{\tau}_{Meta\text{-}SW}$	$\frac{\sigma^2}{n} \sum_{k=1}^{K} \frac{\rho_k}{\rho_k(1-\rho_k)} + \frac{1}{n} \ \beta^{(1)} - \beta^{(0)}\ _{\Sigma}^2$	1	<i>O</i> (1)
Meta-IVW	$\hat{\tau}_{\rm Meta-IVW}$	$\Big(\sum_{k=1}^{K} (\sigma^2 \frac{n\rho_k}{\rho_k(1-\rho_k)} + \frac{1}{n_k} \ \beta^{(1)} - \beta^{(0)}\ _{\Sigma}^2)^{-1} \Big)^{-1}$	1	O(1)
1S-SW	$\hat{\tau}_{\rm 1S-SW}$	$V_{ m pool}$	2	O(d)
1S-IVW	$\hat{\tau}_{\rm 1S-IVW}$	$V_{ m pool}$	2	$O(d^2)$
GD	$\hat{\tau}_{\mathrm{GD}}$	$V_{\rm pool}$	T+1	O(Td)
Pool	$\hat{\tau}_{\rm pool}$	$V_{ m pool} = rac{\sigma^2}{n} rac{1}{p(1-p)} + rac{1}{n} \ eta^{(1)} - eta^{(0)} \ _{\Sigma}^2$	—	_

with $\rho_k := \mathbb{P}(H_i = k) = \mathbb{E}(n_k)/n$ and $p = \sum_{k=1}^{K} \frac{n_k}{n} p_k$.

$$egin{aligned} \mathbb{V}^{\infty}(\hat{ au}_{ extsf{pool}}) &= \mathbb{V}^{\infty}(\hat{ au}_{ extsf{IS-SW}}) \ &= \mathbb{V}^{\infty}(\hat{ au}_{ extsf{IS-SW}}) \ &= \mathbb{V}^{\infty}(\hat{ au}_{ extsf{IS-IVW}}) \end{aligned}$$

$$\begin{split} \mathbb{V}^{\infty}(\hat{\tau}_{\text{pool}}) &= \mathbb{V}^{\infty}(\hat{\tau}_{\text{GD}}) \\ &= \mathbb{V}^{\infty}(\hat{\tau}_{1\text{S}-\text{SW}}) \\ &= \mathbb{V}^{\infty}(\hat{\tau}_{1\text{S}-\text{IVW}}) \\ &\leq \mathbb{V}^{\infty}(\hat{\tau}_{\text{Meta}-\text{IVW}}) \, \end{split}$$

$$\mathbb{V}^{\infty}(\hat{ au}_{pool}) = \mathbb{V}^{\infty}(\hat{ au}_{GD})$$

= $\mathbb{V}^{\infty}(\hat{ au}_{IS-SW})$
= $\mathbb{V}^{\infty}(\hat{ au}_{IS-IVW})$
 $\leq \mathbb{V}^{\infty}(\hat{ au}_{Meta-IVW}) \left\{$
 $\leq \mathbb{V}^{\infty}(\hat{ au}_{Meta-SW}) \left\{$

$$\begin{split} \mathbb{V}^{\infty}(\hat{\tau}_{\text{pool}}) &= \mathbb{V}^{\infty}(\hat{\tau}_{\text{GD}}) \\ &= \mathbb{V}^{\infty}(\hat{\tau}_{1\text{S}-\text{SW}}) \\ &= \mathbb{V}^{\infty}(\hat{\tau}_{1\text{S}-\text{IVW}}) \\ &\leq \mathbb{V}^{\infty}(\hat{\tau}_{\text{Meta}-\text{IVW}}) \begin{cases} = & \text{if same } \{p_k\}_k, \\ \\ &\leq \mathbb{V}^{\infty}(\hat{\tau}_{\text{Meta}-\text{SW}}) \end{cases} \end{cases}$$

$$\begin{split} \mathbb{V}^{\infty}(\hat{\tau}_{\text{pool}}) &= \mathbb{V}^{\infty}(\hat{\tau}_{\text{GD}}) \\ &= \mathbb{V}^{\infty}(\hat{\tau}_{\text{IS-SW}}) \\ &= \mathbb{V}^{\infty}(\hat{\tau}_{\text{IS-IVW}}) \\ &\leq \mathbb{V}^{\infty}(\hat{\tau}_{\text{Meta}-\text{IVW}}) \begin{cases} = & \text{if same } \{p_k\}_k, \\ < & \text{if different } \{p_k\}_k \\ \leq & \mathbb{V}^{\infty}(\hat{\tau}_{\text{Meta}-\text{SW}}) \end{cases} \begin{cases} = & \text{if same } \{p_k(1-p_k)\}_k, \\ < & \text{if different } \{p_k(1-p_k)\}_k \end{cases} \end{split}$$

Comparison of Variances - Homogeneous Setting



Comparison of the Estimators

Heterogeneous Distributions

Distributional Shift:

$$H \not \perp X \implies \mathcal{D}_k \neq \mathcal{D}_I \implies \tau_k \neq \tau_I$$

Figure 1: Graphical model for the heterogeneous distributions setting.



$$\tau = \sum_{k=1}^{K} \rho_k \tau_k$$
 with $\rho_k = \mathbb{E}\left(\frac{n_k}{n}\right)$

Distributional Shift:

$$H \not \perp X \implies \mathcal{D}_k \neq \mathcal{D}_I \implies \tau_k \neq \tau_I$$

Figure 1: Graphical model for the heterogeneous distributions setting.



 $\tau = \sum_{k=1}^{K} \rho_k \tau_k$ with $\rho_k = \mathbb{E}\left(\frac{n_k}{n}\right)$

• $\hat{\tau}_{\text{meta-IVW}} = \frac{\sum_{k=1}^{K} \mathbb{V}(\hat{\tau}_k)^{-1} \hat{\tau}_k}{\sum_{k=1}^{K} \mathbb{V}(\hat{\tau}_k)^{-1}}$ is biased: inverse variance weights do not aim at the $\{\rho_k\}s$.

Distributional Shift:

$$H \not \perp X \implies \mathcal{D}_k \neq \mathcal{D}_I \implies \tau_k \neq \tau_I$$

Figure 1: Graphical model for the heterogeneous distributions setting.



 $\tau = \sum_{k=1}^{K} \rho_k \tau_k$ with $\rho_k = \mathbb{E}\left(\frac{n_k}{n}\right)$

- $\hat{\tau}_{\text{meta-IVW}} = \frac{\sum_{k=1}^{K} \mathbb{V}(\hat{\tau}_k)^{-1} \hat{\tau}_k}{\sum_{i=1}^{K} \mathbb{V}(\hat{\tau}_i)^{-1}}$ is biased: inverse variance weights do not aim at the $\{\rho_k\}s$.
- $\mathbb{V}^{\infty}(\hat{\tau}_{1S-SW})$ is impacted by the different means $\{\mu_k\}_k$.

Distributional Shift:

$$H \not \perp X \implies \mathcal{D}_k \neq \mathcal{D}_I \implies \tau_k \neq \tau_I$$

Figure 1: Graphical model for the heterogeneous distributions setting.



$$\tau = \sum_{k=1}^{K} \rho_k \tau_k$$
 with $\rho_k = \mathbb{E}\left(\frac{n_k}{n}\right)$

- $\hat{\tau}_{\text{meta-IVW}} = \frac{\sum_{k=1}^{K} \mathbb{V}(\hat{\tau}_k)^{-1} \hat{\tau}_k}{\sum_{l=1}^{K} \mathbb{V}(\hat{\tau}_l)^{-1}}$ is biased: inverse variance weights do not aim at the $\{\rho_k\}s$.
- $\mathbb{V}^{\infty}(\hat{\tau}_{1S-SW})$ is impacted by the different means $\{\mu_k\}_k$.

$$\mathbb{V}^{\infty}(\hat{\tau}_{\text{pool}}) \!=\! \mathbb{V}^{\infty}(\hat{\tau}_{\text{GD}}) \!=\! \mathbb{V}^{\infty}(\hat{\tau}_{1\text{S}-\text{IVW}}) \!\leq\! \mathbb{V}^{\infty}(\hat{\tau}_{\text{meta}-\text{SW}})$$

 $\forall k, X_k \sim \mathcal{N}(\mu_k, \Sigma_k)$

Large



Comparison of the Estimators

Presence of Center Effects

Presence of a constant (real-valued) effect of the center k onto the outcome Y:

$$Y_{k,i}^{(w)} = c^{(w)} + \underline{h_k} + X_{k,i}\beta^{(w)} + \varepsilon_i(w)$$

Presence of a constant (real-valued) effect of the center k onto the outcome Y:

$$Y_{k,i}^{(w)} = c^{(w)} + \underline{h_k} + X_{k,i}\beta^{(w)} + \varepsilon_i(w)$$

Studies may have different baselines in individual outcomes, from varying practices or organizational contexts (e.g. hospital specialized in oncology).



Figure 1: Graphical model for the center effects setting.

Presence of a constant (real-valued) effect of the center k onto the outcome Y:

$$Y_{k,i}^{(w)} = c^{(w)} + \underline{h_k} + X_{k,i}\beta^{(w)} + \varepsilon_i(w)$$

Studies may have different baselines in individual outcomes, from varying practices or organizational contexts (e.g. hospital specialized in oncology).



Figure 1: Graphical model for the center effects setting.

Caution: H is now a confounder!

Presence of a constant (real-valued) effect of the center k onto the outcome Y:

$$Y_{k,i}^{(w)} = c^{(w)} + \underline{h_k} + X_{k,i}\beta^{(w)} + \varepsilon_i(w)$$

Properties:

• All federated estimators are **biased** and need to be adjusted **except the metas** which naturally account for the center effects.
Comparison of Variances - Heterogeneity through Center Effects

Presence of a constant (real-valued) effect of the center k onto the outcome Y:

$$Y_{k,i}^{(w)} = c^{(w)} + \underline{h_k} + X_{k,i}\beta^{(w)} + \varepsilon_i(w)$$

Properties:

• All federated estimators are **biased** and need to be adjusted **except the metas** which naturally account for the center effects.

Adjustment:

- Adjusted One-Shot estimators: share and aggregate only the covariates coefficients $\hat{\beta}_k$, while keeping the intercepts local
- Adjusted Gradient Descent: add *H* variable into the datasets.

Comparison of Variances - Heterogeneity through Center Effects

 $(h_1, h_2, h_3, h_4, h_5) = (1, .2, -1, 30, 2)$ and different p_k

Large





Comparison of Variances - Heterogeneity through Center Effects

 $(h_1, h_2, h_3, h_4, h_5) = (1, .2, -1, 30, 2)$ and different p_k





Different $(h_k, p_k, \mu_k, \Sigma_k)$



Different $h_k, p_k, \mu_k, \Sigma_k$

Large





	Meta-Analysis	One-Shot FL Learning	GD FL
+	 Easy to implement Private and low communications: 1 round Shares only summary statistics: Locally estimated ATEs {\$\tilde{\triangle}_k\$} Sample sizes {\$n_k\$} or estimated variances {\$\tilde{V}(\tilde{\triangle}_k)\$} 	 Easy to implement Private and low communications: 2 rounds Shares summary statistics: Sample sizes {nk} or empirical variance-covariance matrices {\$\har{\substack}k\$} (Can be costly when d is large) Locally estimated ATEs with One-Shot federated outcome models {\$\vec{\substack}k\$}\$}\$ 	 Flexible: (non-)parametric models, estimate function τ(X) Robust to locally small sample sizes (n^(w)_k < d) Robust to different treatment schemes Private: using secure aggregation or differential privacy Accurate: learn from the pool dataset as if it was centralized
-	 Sensitive to imbalance in sample sizes No access to individual data: cannot detect and qualify heterogeneity The aggregation with lowest variance (IVW) yields a biased estimate under heterogeneity in distributions 	 Not designed for heterogeneous settings 	 Harder to implement in practice Heavy computations: compute ∇f(θ̂) at each round



Figure 6: Decision Diagram for Practitionners. The sign \star denotes scenarios where the DM estimator is biased.

- Extend this work to **observational studies**.
- Quantify the bias and variances of the estimators in finite sample sizes settings.
- Non-parametric and non-linear approaches: <u>federated random forests</u>, neural networks, etc.
- Apply the **Differential-Privacy** framework to federated causal inferences.

Thank you!

References

- Benkeser, David et al. (2021). "Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes". In: *Biometrics* 77.4, pp. 1467–1481.
- Duflo, Esther, Rachel Glennerster, and Michael Kremer (2007). "Using randomization in development economics research: A toolkit". In: Handbook of development economics 4, pp. 3895–3962.
- European Medicines Agency (2024). ICH E9 Statistical Principles for Clinical Trials: Scientific Guideline.
- French Health Authority (2024). Pricing & Reimbursement of drugs and HTA policies in France. URL: https://www.has-sante.fr/upload/docs/application/pdf/2014-03/pricing_reimbursement_of_drugs_and_hta_policies_in_france.pdf.
- Lei, Lihua and Peng Ding (2021). "Regression adjustment in completely randomized experiments with a diverging number of covariates". In: *Biometrika* 108.4, pp. 815–828.
- Lin, Winston (2013). "Agnostic notes on regression adjustments to experimental data: Reexamining Freedman's critique". In.
- i Moghadas, Seyed M et al. (2021). "The impact of vaccination on coronavirus disease $i^{6/16}$